[99mTc]Tc-Mebrofenin Hepatobiliary Scintigraphy SPECT/CT in the Quantitative Assessment of the Future Liver Remnant Function

Authoring Organization

Publication Month/Year

June 2, 2023

Last Updated Month/Year

August 29, 2023

Document Type


Country of Publication


Document Objectives

The aim of this joint EANM/SNMMI/IHPBA procedure guideline is to provide general information and specific recommendations and considerations on the use of [99mTc]Tc-mebrofenin hepatobiliary scintigraphy (HBS) in the quantitative assessment and risk analysis before surgical intervention,
selective internal radiation therapy (SIRT) or before and after liver regenerative procedures. Although the gold standard to estimate future liver remnant (FLR) function remains volumetry, the increasing interest in HBS and the continuous request for implementation in major liver centers worldwide, demands standardization.

Inclusion Criteria

Male, Female, Adolescent, Adult, Child, Older adult

Health Care Settings

Ambulatory, Outpatient, Radiology services

Intended Users

Nurse, nurse practitioner, physician, physician assistant


Assessment and screening, Management


selective internal radiation therapy, SIRT

Source Citation

Arntz PJW, Deroose CM, Marcus C, Sturesson C, Panaro F, Erdmann J, Manevska N, Moadel R, de Geus-Oei LF, Bennink RJ. Joint EANM/SNMMI/IHPBA procedure guideline for [99mTc]Tc-mebrofenin hepatobiliary scintigraphy SPECT/CT in the quantitative assessment of the future liver remnant function. HPB (Oxford). 2023 Jun 2:S1365-182X(23)00546-4. doi: 10.1016/j.hpb.2023.06.001. Epub ahead of print. PMID: 37394397.